valproic acid has been researched along with Charcot-Marie-Tooth Disease in 4 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Charcot-Marie-Tooth Disease: A hereditary motor and sensory neuropathy transmitted most often as an autosomal dominant trait and characterized by progressive distal wasting and loss of reflexes in the muscles of the legs (and occasionally involving the arms). Onset is usually in the second to fourth decade of life. This condition has been divided into two subtypes, hereditary motor and sensory neuropathy (HMSN) types I and II. HMSN I is associated with abnormal nerve conduction velocities and nerve hypertrophy, features not seen in HMSN II. (Adams et al., Principles of Neurology, 6th ed, p1343)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Memezawa, S | 1 |
| Sato, T | 1 |
| Ochiai, A | 1 |
| Fukawa, M | 1 |
| Sawaguchi, S | 1 |
| Sango, K | 2 |
| Miyamoto, Y | 3 |
| Yamauchi, J | 3 |
| Tatsumi, Y | 1 |
| Matsumoto, N | 1 |
| Iibe, N | 1 |
| Watanabe, N | 1 |
| Torii, T | 2 |
| Homma, K | 1 |
| Sakagami, H | 1 |
| Kusakawa, S | 1 |
| Sanbe, A | 1 |
| Nakamura, K | 1 |
| Takashima, S | 1 |
| Hamasaki, H | 1 |
| Kawaguchi, S | 1 |
| Tanoue, A | 1 |
| Piantino, JA | 1 |
| Torres, A | 1 |
4 other studies available for valproic acid and Charcot-Marie-Tooth Disease
| Article | Year |
|---|---|
The Antiepileptic Valproic Acid Ameliorates Charcot-Marie-Tooth 2W (CMT2W) Disease-Associated HARS1 Mutation-Induced Inhibition of Neuronal Cell Morphological Differentiation Through c-Jun N-terminal Kinase.
Topics: Amino Acyl-tRNA Synthetases; Anticonvulsants; Charcot-Marie-Tooth Disease; Humans; JNK Mitogen-Activ | 2022 |
CMT type 2N disease-associated AARS mutant inhibits neurite growth that can be reversed by valproic acid.
Topics: Alanine-tRNA Ligase; Axons; Charcot-Marie-Tooth Disease; Humans; Mutation; Neurites; Phenotype; Valp | 2019 |
The mood stabilizer valproic acid improves defective neurite formation caused by Charcot-Marie-Tooth disease-associated mutant Rab7 through the JNK signaling pathway.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Charcot-Marie-Tooth Disease; Humans; JNK Mitogen-Activat | 2010 |
Myoclonic seizures in a patient with Charcot-Marie-tooth disease.
Topics: Anticonvulsants; Carbamazepine; Charcot-Marie-Tooth Disease; Child; Developmental Disabilities; Drug | 2007 |